MIT-spinoff Organogenesis announced today that its PuraPly antimicrobial wound care device is now available in a 1.6-cm disc size.
The Canton, Mass.-based company’s PuraPly AM product includes a broad-spectrum antibiotic, polyhexamethylene biguanide, embedded into a purified native collagen matrix. The device is cleared to treat an array of wound types, including pressure ulcers, surgical wounds, trauma wounds and diabetic ulcers.
“A vast majority of wounds – including small ones – contain biofilm, which represents a serious challenge to wound healing,” Gary Gillheeney, Sr., president & CEO, said in prepared remarks. “The new small size of PuraPly AM – which utilizes PHMB to manage bioburden while supporting healing – gives clinicians an exciting new option for treating a wide range of small wounds.”
In March last year, Organogenesis acquired NuTech Medical for an undisclosed price. The deal combined Organogenesis’ wound care products with NuTech’s surgical biologics.
The company also launched a clinical trial program last year for its PuraPly AM device, evaluating the product as an antimicrobial wound management therapy, as well as its ability to manage bioburden, support granulation tissue formation and support wound closure.
